MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Erasca Inc

Cerrado

1.49 0.68

Resumen

Variación precio

24h

Actual

Mínimo

1.46

Máximo

1.6

Métricas clave

By Trading Economics

Ingresos

1.3M

-31M

Empleados

103

EBITDA

-750K

-36M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+200.69% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

20M

414M

Apertura anterior

0.81

Cierre anterior

1.49

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Erasca Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jul 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 jul 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 jul 2025, 21:04 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 jul 2025, 23:43 UTC

Charlas de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 jul 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 jul 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 jul 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 jul 2025, 22:43 UTC

Adquisiciones, fusiones, absorciones

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 jul 2025, 22:43 UTC

Adquisiciones, fusiones, absorciones

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 jul 2025, 22:40 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:40 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:30 UTC

Charlas de Mercado
Ganancias

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 jul 2025, 22:20 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

17 jul 2025, 22:20 UTC

Charlas de Mercado
Ganancias

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 jul 2025, 22:04 UTC

Charlas de Mercado
Ganancias

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 jul 2025, 22:03 UTC

Adquisiciones, fusiones, absorciones

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 jul 2025, 21:58 UTC

Charlas de Mercado
Ganancias

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 jul 2025, 21:57 UTC

Ganancias

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:47 UTC

Ganancias

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 jul 2025, 21:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 jul 2025, 21:45 UTC

Charlas de Mercado

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 jul 2025, 21:38 UTC

Adquisiciones, fusiones, absorciones

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 jul 2025, 21:22 UTC

Adquisiciones, fusiones, absorciones

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 21:05 UTC

Ganancias

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:04 UTC

Adquisiciones, fusiones, absorciones

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 jul 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 20:59 UTC

Adquisiciones, fusiones, absorciones

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

17 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc Esperado

Precio Objetivo

By TipRanks

200.69% repunte

Estimación a 12 meses

Media 4.33 USD  200.69%

Máximo 6 USD

Mínimo 3 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.39 / 1.44Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Very Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.